The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Access · International

What changed in 2026, by region — does this still hold?

Solved
Solved by forest_plot in post #3
Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

Jump to the accepted answer →

SC
sourced_claimsTL3Regular30 Mar 2026#1

What changed in 2026, by region — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below.

Documenting an access outcome, dated, because everything in this category expires.

As of May 2026, in my region, the position is as described below. I have linked the primary source rather than a summary of it, because the summaries are consistently a year behind.

If anyone can confirm or contradict this for their own region, please date your answer. An undated claim in this category is worse than no claim.

3 likes 4mo
HB
h.bakkerTL2 Moderator8 Apr 2026 · edited#2

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

0 likes 4mo
FP
forest_plotTL3Evidence synthesis Solution15 Apr 2026#3

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

18 likes 3mo
NV
n.villalobosTL2 Moderator21 Apr 2026#4

Picking up the opening post: that is the part I would want checked first.

Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.

7 likes 3mo
HS
hana.satoTL427 Apr 2026#5
FA
f.amankwahTL2 Moderator3 May 2026#6
hana.sato, post #5: Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory. Go to post

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

0 likes in reply to #5 3mo
MS
m.strand_rphTL3Pharmacist8 May 2026#7

I read post #5 twice before replying, because I had assumed the opposite.

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

25 likes 3mo
CO
c.ostergaardTL2 Moderator13 May 2026#8

This follows post #5 rather than contradicting it.

Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.

12 likes 3mo
EN
electrolyte_notesTL2Regular18 May 2026 · edited#9

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

0 likes 2mo
ZC
z.cardosoTL2 Moderator22 May 2026#10

post #9 answers the question as asked. The question underneath it is different.

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

26 likes 2mo
D
DOdendaalTL3Regular27 May 2026#11
m.strand_rph, post #7: I read post #5 twice before replying, because I had assumed the opposite. Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk. Go to post

post #10 is right about the mechanism and I think understates the practical bit.

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

0 likes in reply to #7 2mo
CM
c.marchettiTL2 Moderator31 May 2026#12
z.cardoso, post #10: post #9 answers the question as asked. The question underneath it is different. Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt. Go to post

Worth separating two things that post #8 runs together.

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

1 like in reply to #10 2mo
SF
sterile_fileTL3Regular5 Jun 2026 · edited#13

Insurance and coverage: coverage decisions are national. A compound approved in one country might not be covered by insurance in another. Checking both approval and coverage is necessary.

9 likes 2mo
LC
l.cabreraTL2 Moderator9 Jun 2026#14

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

21 likes 2mo
IL
integrator_logTL3Regular13 Jun 2026#15

Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent.

0 likes 1mo
SS
s.salgadoTL2 Moderator18 Jun 2026#16

On post #12 — agreed on the reasoning, with one qualification.

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

2 likes 1mo
VT
vial_tableTL2Member22 Jun 2026#17

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

14 likes 1mo
DV
d.vestergaardTL2 Moderator26 Jun 2026#18
n.villalobos, post #4: Picking up the opening post: that is the part I would want checked first. Import rules for personal use: what you can import for personal use depends on your country's rules, not on where it is sold. Checking your country's rules before ordering is prudent. Go to post

Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).

29 likes in reply to #4 1mo
BE
bench_entryTL3Regular30 Jun 2026#19

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

0 likes 28d
BF
b.friskTL2 Moderator4 Jul 2026#20
sourced_claims, post #1: What changed in 2026, by region — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated, because everything in this category expires. As of May 2026, in my region, the position is as described below. I have linked the primary source rather… Go to post

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

5 likes in reply to #1 24d
NC
n.chowdhuryTL2 Moderator8 Jul 2026#21

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

21 likes 20d
SF
sterile_fileTL3Regular12 Jul 2026 · edited#22
bench_entry, post #19: Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk. Go to post

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

9 likes in reply to #19 16d
SL
s.lundgrenTL2 Moderator15 Jul 2026#23

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

2 likes 12d
AS
a.stephanopoulosTL319 Jul 2026#24
HK
h.kimaniTL2 Moderator23 Jul 2026#25

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

28 likes 5d
B
BDraganovTL2Member27 Jul 2026 · edited#26
h.kimani, post #25: Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks. Go to post

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

14 likes in reply to #25 1d

Suggested topics

TopicParticipantsRepliesViewsActivity
Prescription portability between countries
Prescription portability between countries — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…
SGTLDCIAL+104 114 6.1k 3h
Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
KOSKJNNSMS+72 81 6.9k 8mo
Cross-border purchase within the EU: the actual rules
Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is…
SCMIBVET+6 10 41k 11mo
Personal import allowances, compared
On the subject in the title: Personal import allowances, compared Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of July 2026, in…
BANNKAKSC+5 9 3.2k 7mo
Prescription portability between countries — the long version
On the subject in the title: Prescription portability between countries — the long version Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
HVMRSC 2 182 21h

Related topics — sharing the tags personal import, MHRA, EMA

TopicParticipantsRepliesViewsActivity
[2026 update] EU-wide position versus national implementation
On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…
FIANDT 2 54k 19mo
What a regulator's shortage notice actually authorises
What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. A logistics question, since the answers here are usually better…
BESCAAQLSG+8 12 15k 17h
Pharmaceutical compounding rules, summarised from primary sources — a second dataset
Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. A logistics question, since the…
CRDPICCDJB+50 56 780 8mo
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Documenting an access outcome, dated, because…
CCSGRWIAII+127 150 41k 20mo
NHS criteria and how they are applied in practice — the long version
Posting this under the heading it deserves: NHS criteria and how they are applied in practice — the long version Everything below is what sits behind that. A coverage question with the paperwork detail…
RLJIWTGBST+11 15 11k 9mo